

Express Mail Label No.: EV 312709807 US
Date of Deposit: November 5, 2003



Attorney Docket No. 22058-521

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: *Keith, et al.*

SERIAL 09/521,696
NUMBER:

EXAMINER: J. Seharaseyon

FILING DATE: March 9, 2000

ART UNIT: 1647

FOR: USE OF INTERLEUKIN-11 TO PREVENT IMMUNE-MEDIATED CYTOTOXICITY

Mail Stop IDS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

11/10/2003 MAHMED1 00000024 09521696

01 FC:1806

180.00 OP

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/521,696
	Filing Date	March 9, 2000
	First Named Inventor	Keith
	Group Art Unit	1647
	Examiner Name	J. Seharaseyon
	Attorney Docket Number	22058-521

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AA	4,518,585	05/21/85	Mark, et al.	424	85	
	AB	5,215,895	06/01/93	Bennett, et al.	435	69.52	
	AC	5,270,181	12/14/93	McCoy, et al.	435	69.7	
	AD	5,292,646	03/08/94	McCoy, et al.	435	69.7	
	AE	5,496,830	03/05/96	Shapiro, et al.	514	283	
	AF	5,631,219	05/20/97	Rosenthal, et al.	514	6	
	AG	5,846,958	12/08/98	Capizzi, et al.	514	114	

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	AH	WO 92/04455	GENETICS INSTITUTE, INC.	03/19/92	Yes
	AI	WO 96/19574	GENETICS INSTITUTE, INC.	06/27/96	Yes
	AJ	WO 99/37322	GENETICS INSTITUTE, INC.	07/29/99	Yes
	AK	WO 00/74707	GENETICS INSTITUTE, INC.	12/14/00	Yes

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.